RU58841 showed promise for treating androgenic alopecia but research was halted due to financial and organizational changes. There were no significant safety concerns reported in human trials.
The user shared progress pictures and discussed using minoxidil, finasteride, and a dermaroller for hair loss. They experienced side effects from finasteride and considered adding it to minoxidil to reduce these effects.
Spironolactone, finasteride, and dutasteride are discussed for hair maintenance, with concerns about testosterone and side effects like gynecomastia. Spironolactone is noted for use in both bodybuilding and hormone therapy, with low doses considered for minimizing side effects.
A user is joining a clinical trial for Clascoterone, a drug approved for acne but being tested for hair loss. They previously tried finasteride with limited success and plan to share updates on their experience with the new treatment.
The conversation discusses hair loss treatments, specifically using a Dermaroller, Minoxidil, and RU58841 for two months. The user shared progress pictures showing the results of these treatments.
RU58841 powder from a lab supplier was tested at a free drug testing service. The discussion includes using Minoxidil and finasteride for hair loss treatment.
The conversation is about treatments for androgenetic alopecia, focusing on hyperresponders. Treatments include Minoxidil, finasteride, RU58841, leg training, and cold therapy.
A user is asking about the effectiveness and dosage of RU58841 for hair loss, comparing it to Minoxidil and discussing its long-term use alongside Finasteride. They plan to use RU58841 and Finasteride for several years before potentially switching to GT20029.
Phase II for TDM-105795 for Androgenic Alopecia is set to begin in April 2023. The study aims to evaluate the efficacy and safety of TDM-105795 in male subjects.